Tenvie Therapeutics is developing precision‑engineered small molecule therapies to address core drivers of neurological and peripheral diseases: neuroinflammation and cellular dysfunction.
Leveraging its proprietary product engine, Tenvie has the unique ability to advance both fully CNS‑penetrant and peripherally restricted products across a broad portfolio.
Tenvie’s most advanced program, TNV262, a fully CNS-penetrant NLRP3 inhibitor, is in Phase 1 clinical development for cardiometabolic indications, including obesity and cardiovascular disease, as well as multiple sclerosis.
In parallel, Tenvie is advancing TNV108, a peripherally restricted SARM1 allosteric inhibitor targeting peripheral neuropathies, through preclinical development. Tenvie’s clinical pipeline is complemented by discovery-stage programs across a range of related indications.
